Nilotinib HCL
Product Intro
This is the intermediate of nilotinib. Nilotinib (Tasigna) is a new targeted tumor therapeutic drug, which belongs to tyrosine kinase inhibitor. It is used to treat patients with chronic myeloid leukemia (CML) resistant to imatinib. Gleevec is the preferred drug developed by Novartis for the treatment of chronic myeloid leukemia (CML).
Function
It has a stronger selectivity for bcr-abl kinase activity, has a 30 fold stronger inhibitory effect on tyrosine kinase than imatinib, and can inhibit the kinase activity of BCR-ABL mutant resistant to imatinib. It can also inhibit kit and PDGFR kinase activities.
Application
1. Treat newly diagnosed Philadelphia chromosome positive (Ph +) adult chronic myeloid leukemia in chronic stage.
2. Treat Philadelphia chromosome positive chronic myeloid leukemia in acute and accelerated stage.
3. Treat chronic myeloid leukemia in chronic stage that has been treated with interferon.
4. Children with chronic myeloid leukemia who relapsed after bone marrow suppression or failed to be treated with interferon.
5. Treat Kit (CD117) - positive inoperable or metastatic malignant gastrointestinal stromal tumors.

Copyright © Shanghai Norky Pharmaceutical Co., Ltd. All Rights Reserved 沪ICP备20013299号 Powered by www.300.cn